Axon is a global leader in synthetic biology and molecular R&D, leveraging AI-driven synthesis to eliminate complex chronic diseases. We bridge the gap between biological discovery and human longevity.
Our proprietary AI platform, AXON-GEN, analyzes billions of molecular interactions to predict clinical outcomes with 94% accuracy before first-in-human trials.
Accelerating drug discovery from years to weeks through high-fidelity neural simulations and predictive modeling.
Precision CRISPR-Cas9 applications targeting rare genetic disorders at their fundamental molecular source.
Developing universal vaccines and immune-response systems to protect global populations against future pathogens.
| Therapeutic Area | Program | Discovery | Pre-clinical | Phase I | Phase II | Phase III | Approval |
|---|---|---|---|---|---|---|---|
| Oncology | AX-402 (Solid Tumors) |
|
|||||
| Neurology | AX-109 (Alzheimer's) |
|
|||||
| Cardiology | AX-771 (Heart Failure) |
|
|||||
Axon Biotech (NYSE: AXON) delivers consistent value through rigorous capital allocation and a relentless focus on high-impact clinical candidates.